timothy sykes logo
NYXH Jumps As ACCCESS Trial Data Reset The Trading Map Thumbnail
G Google News

NYXH Jumps As ACCCESS Trial Data Reset The Trading Map

ELLIS HOBBS•UPDATED SEP. 3, 2026, 9:19 AM ET
Reviewed by Jack Kelloggand Fact-checked by Tim Sykes

Nyxoah SA stocks have been trading up by 19.87 percent after positive sleep apnea therapy progress boosted investor optimism.

Key Takeaways

  • ACCCESS pivotal study of Nyxoah’s Genio system in complete concentric collapse sleep apnea met both co‑primary efficacy endpoints at 12 months with no device-related serious adverse events.
  • The trial showed a 77.2% responder rate and supports a planned FDA PMA supplement to expand Genio’s U.S. label into a currently untreated obstructive sleep apnea population.
  • NYXH shares spiked about 15% after the ACCCESS data, signaling growing trader confidence in a broader U.S. indication for the Genio system.
  • Oppenheimer cut its Nyxoah price target to $4 from $13 but kept an Outperform rating and FY26 revenue guidance after reporting €7.7M in Q2 net revenue.
  • Cantor Fitzgerald and Piper Sandler both trimmed NYXH targets yet maintained Overweight ratings, pointing to strong U.S. commercialization momentum and a solid growth foundation.

Candlestick Chart

Live Update At 09:18:53 EDT: On Thursday, September 03, 2026 Nyxoah SA stock [NASDAQ: NYXH] is trending up by 19.87%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

NYXH has been trading like a slow grinder on the daily chart. From 2026/08/10 to 2026/09/02, Nyxoah’s share price drifted from around $1.58 to $1.51, with plenty of closes clustered between $1.58 and $1.64. That tight range tells traders the market was waiting on a real catalyst.

Intraday, the latest 5‑minute tape looks different. NYXH pushed from roughly $1.65 at 06:30 to above $1.80 by the open around 09:15, reflecting the ~15% spike tied to the ACCCESS trial news. That push shows fresh momentum, with higher lows through the premarket and into the open, exactly the kind of staircase pattern momentum traders on NYXH like to see.

More Breaking News

Fundamentally, Nyxoah is still in early commercialization mode. Revenue over the last year sits near $10.0M, yet the price‑to‑sales ratio around 12.9 says the market is already paying up for growth potential. Return on equity near -11% and very negative pretax margins show NYXH is losing money while it scales. The balance sheet, with roughly $48.0M in cash and total assets of $118.5M against $69.3M in liabilities, gives the company some runway. For traders, that combination—tight float‑style price action, clinical catalysts, and a still‑loss‑making profile—sets the stage for volatile swings around every data headline.

Why Traders Are Watching NYXH Right Now

NYXH is firmly on radar this week because the ACCCESS U.S. pivotal trial finally delivered the type of data traders want to see. Nyxoah reported that the ACCCESS study in complete concentric collapse obstructive sleep apnea patients hit all primary safety and efficacy endpoints at 12 months. A 77.2% AHI responder rate, with no device‑related serious adverse events, is a strong readout in a tough, currently untreated population.

For NYXH, this matters because it supports a planned FDA PMA supplement to broaden the U.S. label for the Genio hypoglossal nerve stimulation system. Translation for traders: the potential addressable market in the U.S. gets bigger if the FDA signs off. The Breakthrough Device Designation already in place could help speed that process, which is why NYXH ripped roughly 15% on the news.

At the same time, Wall Street has been resetting its numbers. Oppenheimer slashed its Nyxoah price target to $4 from $13, but it kept an Outperform rating and backed FY26 revenue guidance after €7.7M in Q2 net revenue, including €5.2M from the U.S. In parallel, Cantor Fitzgerald trimmed its NYXH target to $6 from $11 and still calls the stock Overweight, highlighting 89 new U.S. accounts and 55 additional surgeons in Q2 to support a 10%–15% market share goal. Piper Sandler also nudged its target down to $6 while staying Overweight, citing a solid base for future growth.

Despite the target cuts, NYXH maintains an overall overweight profile and an average Street target around $6.01 versus a share price near $1.50 before the ACCCESS spike. That spread is exactly why momentum and swing traders are circling NYXH: big perceived upside, but tied to binary regulatory and execution milestones.

Conclusion

NYXH now sits at the intersection of powerful clinical news and a still‑discounted chart. The ACCCESS data show the Genio system delivering strong efficacy and clean safety in complete concentric collapse patients, a group that has lacked good options. If the FDA accepts Nyxoah’s planned PMA supplement and broadens the U.S. label, NYXH’s revenue story can change quickly, and the recent 15% pop might be only the first leg of a longer trend. But traders also know that until approval actually lands, this is still a development‑stage commercial story with negative margins and a rich sales multiple.

Analyst action reinforces that split personality. Oppenheimer, Cantor Fitzgerald, and Piper Sandler all lowered their Nyxoah price targets, yet every one of them stuck with constructive ratings on NYXH and pointed to tangible U.S. traction—new accounts, more surgeons, growing U.S. revenue. The average target near $6.01 against a stock that recently traded around the mid‑$1s shows how wide the expectations gap remains.

For active traders, NYXH is a classic catalyst name: clear news drivers, real volume, and plenty of volatility. As Tim Sykes likes to say, “the market rewards preparation, not prediction”—and NYXH is the type of ticker where that mindset matters. As millionaire penny stock trader and teacher Tim Sykes, says, “The goal is not to win every trade but to protect your capital and keep moving forward.”. Study the ACCCESS news, map the key FDA and commercialization dates, and let the price action—not emotions—dictate your trading plans. This coverage is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”